Bioray Pharmaceutical Co., Ltd.
Clinical trials sponsored by Bioray Pharmaceutical Co., Ltd., explained in plain language.
-
New gout pill aims to tame uric acid in Mid-Stage trial
Disease control Not yet recruitingThis study tests a new tablet called BR2251 to see if it can safely lower uric acid levels in people with gout and high uric acid. About 160 adults will receive either a low, medium, or high dose of BR2251 or a control drug for 12 weeks. The goal is to find the best dose to contr…
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug BRY812 targets Hard-to-Treat gynecologic cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called BRY812 in people with advanced gynecologic cancers (ovarian, endometrial, or ovarian clear cell) that have a specific marker called LIV-1. The goal is to see if the drug can shrink tumors. About 56 participants will receive the drug, and researc…
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 05, 2026 11:55 UTC